Fundraising FoxQR Pharma
NYSE: ANVSBerwyn, US · Delaware corporation · 4 known investors
Find your way into QR Pharma
QR Pharma is a clinical-stage biopharmaceutical company developing buntanetap, an orally administered small molecule that inhibits the synthesis of multiple neurotoxic proteins implicated in Alzheimer's disease and Parkinson's disease. The company is conducting pivotal Phase 3 trials in early Alzheimer's disease and an open-label extension study in Parkinson's disease, with additional studies planned for Parkinson's disease dementia.
Founders & leadership
MM
Maria MaccecchiniFounder
Board
DG
Dhesh GovenderBoard director
MH
Michael HoffmanBoard director
FF
Franz F. HeftiBoard director
Investors · 4
Keiretsu Forumlisted by Keiretsu ForumSan Francisco East Bay · $250K – $2M
How we know: Keiretsu Forum's portfolio page · Not right? Tell us
Ben Franklin Technology PartnersreportedHarrisburg · $50K – $250K
How we know: the S-1 prospectus · Not right? Tell us
BioAdvancereportedConshohocken · $500K – $1.5M
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$3.8M disclosed across 5 rounds · 2015–2023
▶$1.1MraisedApr 2023 · 6 investors · BiotechnologyRule 506(b)
▶$1.1MraisedApr 2023 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Claudine BruckDirector
- Mark WhiteDirector
- Reid McCarthyDirector
- Michael HoffmanDirector
- Henry HagopianExecutive Officer
- Maria MaccecchiniExecutive Officer, Director
- Offering amount
- $1.1M
- Amount sold
- $1.1M
- First sale
- Apr 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$530KraisedMar 2019 · 9 investors · PharmaceuticalsRule 506(b)
▶$530KraisedMar 2019 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert WhelanDirector
- Maria L. MaccecchiniExecutive Officer, Director
- Michael HoffmanDirector
- Claudine BruckDirector
- Mark WhiteDirector
- Offering amount
- $530K
- Amount sold
- $530K
- Proceeds to insiders
- $55K
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$324KraisedDec 2017 · 6 investors · PharmaceuticalsRule 506(b)
▶$324KraisedDec 2017 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Maria L. MaccecchiniExecutive Officer, Director
- Mark WhiteDirector
- Michael HoffmanDirector
- Claudine BruckDirector
- Robert WhelanDirector
- Offering amount
- $1M
- Amount sold
- $324K
- Proceeds to insiders
- $120K
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$799.2KraisedOct 2016 · 14 investors · PharmaceuticalsRule 506(b)
▶$799.2KraisedOct 2016 · 14 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Maria L. MaccecchiniExecutive Officer, Director
- Michael HoffmanDirector
- Claudine BruckDirector
- Robert WhelanDirector
- Mark WhiteDirector
- Offering amount
- $799.2K
- Amount sold
- $799.2K
- Proceeds to insiders
- $120K
- First sale
- Oct 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedJun 2015 · 21 investors · PharmaceuticalsRule 506(b)
▶$1.1MraisedJun 2015 · 21 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Dhesh GovenderDirector
- Michael HoffmanDirector
- Maria MaccecchiniExecutive Officer, Director
- Franz F. HeftiDirector
- Offering amount
- $1.1M
- Amount sold
- $1.1M
- Proceeds to insiders
- $120K
- First sale
- May 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$38.4Mvaluation at IPOJan 2020 · $6.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 4
BioQ PharmaBioQ Pharma is a pharmaceutical company with expertise in biotech development and healthcare technology. The company appears to be focused on pharmaceutical innovation with a board of directors drawn from senior executives with extensive experience in biotech, medical devices, and pharma commercialization.
LeadIQLeadIQ offers a company search tool that provides B2B company profiles with data such as revenue, employee count, funding, and contact information to help sales teams find decision makers and build pipeline.
STAQ PharmaSTAQ Pharma is an FDA-registered 503B outsourcing facility that compounds and supplies medications to hospitals and healthcare providers across the United States, aiming to address drug shortages. The company is owned and guided by several healthcare systems and focuses on safety, transparency, availability, and quality.
WazeWorld's largest community-based traffic and navigation app.
Companies working in the same space as QR Pharma.
In the news
Frequently asked questions
- What does QR Pharma do?
- QR Pharma is a clinical-stage biopharmaceutical company developing buntanetap, an orally administered small molecule that inhibits the synthesis of multiple neurotoxic proteins implicated in Alzheimer's disease and Parkinson's disease. The company is conducting pivotal Phase 3 trials in early Alzheimer's disease and an open-label extension study in Parkinson's disease, with additional studies planned for Parkinson's disease dementia.
- Who founded QR Pharma?
- QR Pharma was founded by Maria Maccecchini.
- Who are QR Pharma's investors?
- QR Pharma's investors include Keiretsu Forum, Ben Franklin Technology Partners, BioAdvance, Robin Hood Ventures.
- How much funding has QR Pharma raised?
- QR Pharma has disclosed $3.8M raised across 5 rounds.
- Where is QR Pharma headquartered?
- QR Pharma is headquartered in Berwyn, US.